Update on the Combination of Myo-Inositol/D-Chiro-Inositol for the Treatment of Polycystic Ovary Syndrome

January 2024 in “ Gynecological Endocrinology ”

Iñaki Lete, Ainara Martínez, Irene Lasaga, Eva Centurión, Amaia Vesga

myo-inositol D-chiro-inositol polycystic ovary syndrome insulin sensitivity ovulatory function oocyte quality metformin PCOS MYO DCI

Studysummary This narrative review on inositol use in PCOS treatment found positive results for myo-inositol alone and effective outcomes for a myo-inositol/D-chiro inositol combination at a 40:1 ratio, suggesting further research on other combinations like 66:1 to 100:1.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The review examines the use of myo-inositol (MYO) and D-chiro-inositol (DCI) for treating polycystic ovary syndrome (PCOS), finding that MYO alone and in combination with DCI at a 40:1 ratio are effective, particularly for improving insulin sensitivity, ovulatory function, and oocyte quality. A meta-analysis of nine clinical trials involving 247 PCOS patients supports the efficacy and safety of these treatments compared to traditional options like metformin. The review suggests that while the 40:1 ratio is effective, further research into higher MYO ratios, such as 66:1 to 100:1, could enhance treatment outcomes. Maintaining a proper inositol ratio is crucial, as higher DCI concentrations can negatively impact reproductive outcomes.

View this study on tandfonline.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Androgenetic Alopecia From A to Z

2 citations , January 2022 in “Springer eBooks”

research Therapeutic Approach for Metabolic Disorders and Infertility in Women with PCOS

54 citations , August 2017 in “Gynecological Endocrinology”

This review discusses treatments for polycystic ovary syndrome, including lifestyle changes, oral contraceptives, and various medications, and reports no new clinical findings; the authors highlight the potential of statins and inositol for managing symptoms.

Metformin: An Old Medication of New Fashion: Evolving New Molecular Mechanisms and Clinical Implications in Polycystic Ovary Syndrome

research Metformin: An Old Medication of New Fashion: Evolving New Molecular Mechanisms and Clinical Implications in Polycystic Ovary Syndrome

200 citations , October 2009 in “European journal of endocrinology”

This review discusses the multifaceted actions of metformin in polycystic ovary syndrome and reports no new clinical results; the authors emphasize metformin's potential benefits in both cardiometabolic and reproductive aspects of PCOS.